Obstructive sleep apnea after 50: what the evidence shows about diagnosis, CPAP, and newer options

Obstructive sleep apnea (OSA) is one of the most common and least recognized sleep disorders in people over 50. This article reports what the published evidence shows about how OSA is diagnosed and treated. It is evidence reporting, not medical guidance.

What obstructive sleep apnea is

In OSA, the muscles that hold the upper airway open relax during sleep and the airway narrows or closes. Breathing pauses (apneas) or shallow breaths (hypopneas) follow, often ending in a brief arousal and a drop in blood oxygen. The standard measure of severity is the apnea-hypopnea index (AHI), the number of these events per hour of sleep. The American Academy of Sleep Medicine (AASM) classifies an AHI of 5 to 14.9 as mild, 15 to 29.9 as moderate, and 30 or higher as severe (Sleep Foundation summary of AASM criteria).

How common it is in older adults

OSA is strongly age-related. Epidemiologic reviews report that prevalence rises sharply after middle age and approaches roughly 50 percent in adults over 65 by common AHI thresholds, higher still in those over 80 (Epidemiology of Adult OSA, PMC). An AASM Foundation study published in the Journal of the American Geriatrics Society found that about 56 percent of adults 65 and older were at high risk for OSA, yet only around 8 percent had been tested (AASM Foundation). Older adults often do not fit the classic picture of a loud-snoring, sleepy, thick-necked patient, which is part of why the condition is underdiagnosed.

How it is diagnosed

The AASM 2017 clinical practice guideline states that in-laboratory polysomnography is the reference standard for diagnosing OSA in adults with a clinical concern (Kapur et al., JCSM, 2017). For uncomplicated adults whose history and symptoms point to an increased risk of moderate-to-severe OSA, either polysomnography or a home sleep apnea test with an adequate device can be used. If a home test is negative, inconclusive, or technically inadequate, the guideline calls for in-lab polysomnography. It also recommends polysomnography rather than home testing for people with significant heart or lung disease, neuromuscular weakness, suspected hypoventilation, chronic opioid use, or prior stroke, categories that overlap heavily with older patients.

Health links

OSA is associated with daytime sleepiness, impaired concentration, and reduced quality of life, and observational data link it with hypertension, atrial fibrillation, coronary disease, stroke, and type 2 diabetes. Much of this evidence is associative rather than proof of cause, and confounders such as obesity and age are hard to fully separate. The treatment trials below help clarify where intervening changes outcomes and where it does not.

CPAP: symptoms versus cardiovascular events

Continuous positive airway pressure (CPAP) delivers pressurized air through a mask to hold the airway open. A meta-analysis of 41 randomized trials in 7,332 patients found CPAP improved daytime sleepiness, with a weighted mean reduction of about 2.1 points on the Epworth Sleepiness Scale (PMC meta-analysis, 2022). For symptom relief, quality of life, and snoring, the evidence for CPAP is consistent.

The cardiovascular story is more nuanced. The SAVE trial randomized 2,717 adults aged 45 to 75 with moderate-to-severe OSA and established cardiovascular disease to CPAP plus usual care or usual care alone. Over an average of 3.7 years, CPAP did not reduce cardiovascular events (NEJM, 2016). It did reduce snoring and daytime sleepiness and improved mood and quality of life. A key caveat is adherence: average CPAP use was only 3.3 hours a night, below the level some argue is needed for cardiovascular benefit. The trial cannot rule out that better-used CPAP might help, but it did not demonstrate event reduction as delivered.

The adherence problem

CPAP only works while it is worn. Reviews report that nonadherence, often defined as under 4 hours a night, ranges widely, from roughly 29 percent to over 80 percent across studies, with long-term use in some cohorts as low as 30 percent (Determinants of CPAP adherence, PLOS One). Adherence tends to be higher in severe OSA and in people who use the device consistently in the first weeks. This gap between efficacy and real-world use shapes why alternatives matter.

Oral appliances

Mandibular advancement devices reposition the lower jaw forward to enlarge the airway. Systematic reviews find CPAP lowers AHI more than oral appliances, yet the two often produce comparable improvements in symptoms and quality of life, in part because patients wear appliances more consistently (CPAP vs MAD meta-analysis, PMC). The AASM considers oral appliances a reasonable option for mild-to-moderate OSA and for patients who cannot tolerate CPAP.

Weight loss and the GLP-1 evidence

Weight is a major modifiable driver of OSA. The SURMOUNT-OSA program tested tirzepatide, a GLP-1/GIP receptor agonist, in adults with obesity and moderate-to-severe OSA across two 52-week randomized trials, one in people not using PAP and one in PAP users (NEJM, 2024). Tirzepatide reduced AHI by about 25 to 29 events per hour versus roughly 5 with placebo, a relative reduction of about 51 percent in the non-PAP group and 59 percent in the PAP group, alongside about 18 to 20 percent weight loss and lower blood pressure. The trials were funded by Eli Lilly. On this basis the FDA approved tirzepatide (Zepbound) in December 2024 for moderate-to-severe OSA in adults with obesity, as an adjunct to reduced-calorie diet and increased activity, not as a replacement for PAP (Eli Lilly/FDA). Longer-term data on symptoms and cardiovascular outcomes are still limited.

Positional therapy and nerve stimulation

Some people have supine-predominant OSA that worsens on the back. A meta-analysis of positional therapy found about a 54 percent reduction in AHI and a large drop in supine sleep time (Positional modification meta-analysis). For selected patients who cannot use CPAP, hypoglossal nerve stimulation (an implanted device that activates the tongue muscles) reduced median AHI by 68 percent at 12 months in the STAR trial, from 29.3 to 9.0 events per hour, with durable results reported at 5 years (NEJM, 2014).

This article is evidence reporting and not medical advice. Testing and treatment choices for sleep apnea depend on your individual health, and should be discussed with a qualified clinician.

Common questions

Do I need an overnight lab test, or is a home sleep test enough?

The AASM 2017 guideline says in-lab polysomnography is the reference standard, but a home sleep apnea test can be used for uncomplicated adults judged to be at increased risk of moderate-to-severe OSA. Home tests are not recommended when significant heart or lung disease, neuromuscular weakness, suspected hypoventilation, chronic opioid use, or prior stroke is present, and a negative or inconclusive home test should be followed by in-lab testing. A clinician decides which path fits.

Does CPAP prevent heart attacks and strokes?

The evidence is mixed. CPAP clearly reduces snoring and daytime sleepiness and improves quality of life. But the large SAVE trial found it did not reduce cardiovascular events in people with OSA and existing heart disease, though average use was only 3.3 hours a night. Whether more consistent use changes cardiovascular risk is not settled.

Can weight-loss drugs like Zepbound treat sleep apnea?

In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index by roughly 48 to 56 percent versus placebo in adults with obesity and moderate-to-severe OSA, and the FDA approved it (as Zepbound) for this use in December 2024. It is approved as an adjunct to diet and activity, not as a replacement for CPAP, and long-term outcome data are still limited.

What are the options if I cannot tolerate CPAP?

Trial and review evidence supports several alternatives, including mandibular advancement (oral) appliances for mild-to-moderate OSA, positional therapy for people whose apnea is worse on their back, weight loss, and hypoglossal nerve stimulation for selected patients. Each has different evidence and trade-offs, and suitability depends on the individual.

Why is sleep apnea missed so often in older adults?

Prevalence rises with age and approaches or exceeds 50 percent in some older groups, but symptoms in older adults may not match the classic profile of loud snoring, sleepiness, and a large neck. Surveys suggest a large majority of at-risk older adults have never been tested.